Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer (vol 17, 66, 2023)

Abstract

Following publication of the original article [1], the authors reported that some words in Table 1 were out of alignment and it needed to be corrected. The correct Table 1 has been provided in this correction. (Table presented.) Demographic and clinicopathological characteristics of patient cohort Characteristics (n = 55) n (%) Chinese 50 (90.9) Others 5 (9.1) Never-smoker 52 (94.5) Smoker 3 (5.5) Temporal occurrence of lung and breast cancer diagnosis Lung cancer occurred first 5 (9.1) Breast cancer occurred first 38 (69.1) Synchronous (within 6 months) 12 (21.8) Family cancer history (any primary) First degree 27 (49.1) Second degree 4 (7.3) No known history 24 (43.6) First degree 8 (14.5) Second degree 2 (3.6) Breast cancer Lung cancer Diagnosis year 1976–2018 Diagnosis year 2005–2018 Median age, years (range) 55 (34–81) Median age, years (range) 65 (48–78) Ductal carcinoma in situ (DCIS) 5 (9.1) Adenocarcinoma (ADC) 44 (80) Infiltrating ductal carcinoma (IDC) 33 (60) Neuroendocrine carcinoma Infiltrating lobular carcinoma (ILC) 4 (7.3) Carcinoid 2 (3.6) DCIS + DCIS (bilateral) 1 (1.8) SCLC 3 (5.5) IDC + DCIS (bilateral) 2 (3.6) Undifferentiated 1 (1.8) IDC + ILC (bilateral) 2 (3.6) Lymphoepithelioma-like carcinoma (LELC) 1 (1.8) IDC + unknown subtype (bilateral) 1 (1.8) ADC + carcinoid (bilateral, synchronous) 1 (1.8) Mucinous adenocarcinoma 3 (5.5) ADC + ADC (bilateral, synchronous) 1 (1.8) Subtype not specified (NOS) 4 (7.3) ADC + ADC (same side, synchronous) 2 (3.6) 0 6 (10.9) 0 0 (0.0) I/II 44 (80.0) I/II 26 (47.3) III 4 (7.3) III 7 (12.7) IV 1 (1.8) IV 22 (40.0) EGFR status (adenocarcinoma only, n = 49) Not tested 4 (8.2) Positive 36 (65.4) Tested 45 (91.8) Negative 10 (18.2) 33 (73.3*) Not tested/unknown 9 (16.4) Exon19 del 19 (57.6^) L858R 11 (33.3^) Positive 30 (54.5) Others 3 (9.1^) Negative 15 (27.3) 12 (26.7*) Not tested/unknown 10 (18.2) Positive 4 (7.3) Negative 28 (50.9) Not tested/unknown/equivocal 23 (41.8) aFor bilateral cancers, higher stage was taken bAll 4 multi-lesion cases are stage I cFor bilateral cancers, higher stage’s status was presented *Over tested cases (total n = 45) ^Over mutant cases (total n = 33) The original article [1] has been corrected.